Kepler Capital analyst Christophe dombu maintained a Buy rating on MaaT Pharma (MAAT – Research Report) on March 27 and set a price target of €16.50. The company’s shares closed yesterday at €6.10.

According to TipRanks, dombu is ranked #7183 out of 9406 analysts.

MaaT Pharma has an analyst consensus of Moderate Buy, with a price target consensus of €19.25, a 215.57% upside from current levels. In a report released on March 27, Stifel Nicolaus also maintained a Buy rating on the stock with a €22.00 price target.

The company has a one-year high of €9.96 and a one-year low of €5.66. Currently, MaaT Pharma has an average volume of 6,795.